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Blood vessel stability is essential for embryonic
development; in the adult, many diseases are as-
sociated with loss of vascular integrity. The ETS
transcription factor ERG drives expression of VE-
cadherin and controls junctional integrity. We show
that constitutive endothelial deletion of ERG
(ErgcEC-KO) in mice causes embryonic lethality with
vascular defects. Inducible endothelial deletion of
ERG (ErgiEC-KO) results in defective physiological
and pathological angiogenesis in the postnatal retina
and tumors, with decreased vascular stability. ERG
controls the Wnt/b-catenin pathway by promoting
b-catenin stability, through signals mediated by VE-
cadherin and the Wnt receptor Frizzled-4. Wnt
signaling is decreased in ERG-deficient endothelial
cells; activation of Wnt signaling with lithium chlo-
ride, which stabilizes b-catenin levels, corrects
vascular defects in ErgcEC-KO embryos. Finally, over-
expression of ERG in vivo reduces permeability and
increases stability of VEGF-induced blood vessels.
These data demonstrate that ERG is an essential
regulator of angiogenesis and vascular stability
through Wnt signaling.
INTRODUCTION
Angiogenesis is essential during embryogenesis and is a critical
component of many diseases. Coordination of growth and stabil-
ity signals is required for effective angiogenesis (Jain, 2003).
Diseases such as cancer, diabetic retinopathy, and vascularmal-82 Developmental Cell 32, 82–96, January 12, 2015 ª2015 The Authoformations are associated with vascular instability, which causes
increased permeability and edema, excessive and/or dysfunc-
tional angiogenesis, and hemorrhage. New strategies that target
the maturation of blood vessels and restore vascular integrity
could therefore have important therapeutic implications.
Multiple interactions at endothelial cell-cell junctions control
vascular integrity. Crucial among these are the adhesion mole-
cule vascular endothelial (VE)-cadherin and its intracellular part-
ner b-catenin, an essential component of the canonical Wnt
pathway (reviewed in Dejana, 2010). b-catenin is a multifunc-
tional protein that can act as a scaffold between VE- and N-cad-
herins and the actin cytoskeleton, and as a coregulator for the
T cell factor (TCF)/lymphoid enhancer-binding factor transcrip-
tion factor complex. b-catenin levels are controlled by phosphor-
ylation through a cytoplasmic degradation complex (reviewed in
Reis and Liebner, 2013; Dejana, 2010). In the presence of Wnt li-
gands, which bind to a receptor complex containing members of
the Frizzled (Fzd) family, the degradation complex is inactivated;
b-catenin is stabilized and translocates to the nucleus to pro-
mote transcription. In the vasculature, the Wnt/b-catenin
pathway controls vascular stability through remodeling, junction
assembly, and pericyte recruitment (reviewed in Reis and Lieb-
ner, 2013; Dejana, 2010; Franco et al., 2009).
The ETS transcription factor family is implicated in vascular
development and angiogenesis (reviewed in Randi et al., 2009).
The ETS related gene (ERG), expressed throughout the life of
the endothelium, regulates multiple pathways involved in
vascular homeostasis and angiogenesis, such as monolayer
integrity, endothelial permeability, and survival (Birdsey et al.,
2008, 2012; Yuan et al., 2012). Previous studies have indicated
a role for ERG in vascular development and angiogenesis (Balt-
zinger et al., 1999; Birdsey et al., 2008; Liu and Patient, 2008).
Vijayaraj et al. reported that global deletion of a subset of endo-
thelial ERG isoforms in mice results in defects in vascular and
cardiac morphogenesis, causing embryonic lethality (Vijayarajrs
Figure 1. ERG Is Required for Vascular Development, Physiological Postnatal Angiogenesis, and Pathological Tumor Angiogenesis
(A) Representative whole mount images of E10.5 Ergfl/fl and ErgcEC-KO embryo yolk sacs (magnification 3 0.7). Bottom panel shows higher magnification of yolk
sacs (magnification 3 2).
(legend continued on next page)
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et al., 2012). Themechanisms throughwhich ERG controls blood
vessel formation are still unclear, and its therapeutic potential is
unexplored.
In this study, we use genetic lineage-specific mouse models
andmultiple in vitro models to show that ERG promotes vascular
growth and stability, through control of the canonical Wnt/b-cat-
enin pathway. Crucially, we demonstrate that overexpression
of ERG in vivo enhances vascular endothelial growth factor
(VEGF)-dependent angiogenesis and promotes stability of
VEGF-induced new blood vessels.
RESULTS
Endothelial ERG Is Required for Vascular Development,
Angiogenesis, and Tumor Growth
To investigate the role of endothelial ERG in vivo, we used a Cre/
loxP strategy. The floxed allele of Erg was obtained by inserting
two loxP sites flanking exon 6 (Figure S1A available online).
Constitutive endothelial-specific deletion of Erg was achieved
by breeding floxed Ergmice with mice expressing the Cre trans-
gene under the control of the Tie2 promoter and enhancer
(Kisanuki et al., 2001). Homozygous deletion of endothelial Erg
(Tie2Cre-Ergfl/fl; henceforth referred to as ErgcEC-KO) resulted in
embryonic lethality between embryonic day (E)10.5 and E11.5,
with no live offspring (Figure S1B). Analysis of the yolk sacs
from ErgcEC-KO embryos at E10.5 showed a significant reduction
in perfused large vessels, consistent with defects in yolk sac
vascular remodeling (Figures 1A, 5E, and 5F). Between E10.5
and E11.5, some mutant embryos appeared pale with no evi-
dence of vessel blood flow, whereas others displayed hemor-
rhages and an enlarged pericardial cavity, suggesting defective
heart function (Figures S1C and S1D). ErgcEC-KO embryos were
reduced in size compared to littermate controls (Figure 1B),
with growth retardation clearly visible at E9.5 (Figure S1E). These
results are in agreement with the phenotypes caused by global
deletion of endothelial ERG isoforms (Vijayaraj et al., 2012). En-
domucin staining of blood vessels in ErgcEC-KO embryos at
E10.5 revealed an immature disorganized vascular plexus, with
significant disruption of the large vessels in the cranial vascula-
ture (Figure 1B, panels a and b), altered development of the hy-
aloid vessels of the eye (Figure S1F), and irregular blind ending
vessels in the head microvasculature (Figure S1G). Mutant em-
bryos also exhibited disorganization of the intersomitic vessels
in the trunk (Figure 1B, panel c). These data confirm that ERG
is required for vascular development in mice.
To investigate the role of ERG in physiological and patholog-
ical postnatal angiogenesis, floxed Erg mice were bred with
mice carrying tamoxifen-inducible Cre recombinase under the
control of the Cdh5 promoter (Cdh5(PAC)-iCreERT2) (Wang(B) Endomucin staining of blood vessels in E10.5 Ergfl/fl and ErgcEC-KO embryos;
head region (panels a and b; scale bars, a, 200 mm and scale bars, b, 100 mm) a
(C) Isolectin B4 staining of postnatal day 6 retinas from Ergfl/fl and ErgiEC-KO mice
(D) Vascular density of isolectin B4 stained branches in the central plexus, scale
(E) EC sprouts at the angiogenic front (arrows), scale bar, 100 mm; quantification
(F) Representative images of B16F0 tumors which were grown for 14 days on ad
(n = 6).
(G and H) Panels show endomucin staining of blood vessels in B16F0 tumors and
bar, 50 mm. All graphical data are ± SEM, *p < 0.05, and ***p < 0.001. See also F
84 Developmental Cell 32, 82–96, January 12, 2015 ª2015 The Authoet al., 2010). Following tamoxifen administration, efficient Cre-re-
combinase deletion of Erg was confirmed by PCR in Ergfl/fl/
Cdh5(PAC)-iCreERT2 mice (henceforth referred to as ErgiEC-KO)
(Figure S1H). The reduction in ERG protein levels was de-
monstrated by western blotting and immunofluorescence
microscopy (Figures S1I and S1J). In the retinal vasculature of
littermate controls (Ergfl/fl), ERGwas strongly expressed in endo-
thelial cells (EC) from all regions of the vascular plexus, including
tip and stalk cells, arteries, veins, and capillaries (Figure S1K), in
line with previous studies (Korn et al., 2014). Deletion of endothe-
lialErg resulted in significant reduction of vascular coverage (Fig-
ure 1C) and density (Figure 1D) in the retinal plexus, and reduc-
tion in the number of vascular sprouts at the front (Figure 1E).
Next, we investigated whether ERG is involved in pathological
angiogenesis, using the B16F0 melanoma tumor model, which
depends on angiogenesis for growth (Reynolds et al., 2002). At
day 14, tumor size and microvessel density were significantly
reduced in adult ErgiEC-KO mice compared to controls (Figures
1F–1H). These studies confirm that ERG is required for postnatal
angiogenesis and show that endothelial ERG is involved in tumor
angiogenesis and tumor growth.
ERG Controls Vascular Stability and Pericyte Coverage
Co-staining for isolectin B4 and the basement matrix component
collagen IV showed a greater number of empty collagen IV
sleeves in the capillary plexus (Figure 2A) and at the angiogenic
front (Figure S2A) in retinas from ErgiEC-KO mice compared to
controls, indicating increased vessel regression. Pericyte
recruitment, measured by staining with neuron-glial antigen 2
(NG2) and desmin, was significantly decreased along all vessels
in the vascular plexus, including veins and arteries in ErgiEC-KO
mice (Figures 2B, S2B, and S2C). Similar signs of decreased
vessel stability were observed in tumors grown in ErgiEC-KO
mice, with a marked increase in the number of empty collagen
IV sleeves (Figure 2C) and a reduction in pericyte coverage of
blood vessels (Figure 2D). These data suggest that ERG controls
both physiological and pathological angiogenesis through path-
ways that promote vascular stability.
ERG Controls b-Catenin Stability and Signaling through
VE-Cadherin- and Wnt-Dependent Mechanisms
In vitro studies have shown that ERG is essential to maintain
the integrity of endothelial junctions, by driving expression of
VE-cadherin (Gory et al., 1998; Birdsey et al., 2008). A marked
reduction in VE-cadherin expression and junctional localization
was also observed in the retinal vasculature of ErgiEC-KO mice
(Figure 3A), demonstrating that loss of endothelial ERG leads
to a disruption of cell-cell junctions in vivo. Isolated primary
mouse lung EC from heterozygous Tie2Cre-Ergfl/+ micescale bars, 1 mm. Higher magnification of embryos shows vessel detail in the
nd the trunk (panel c, scale bar, 200 mm).
, showing vascular progression, scale bar, 500 mm; quantification (n = 6).
bar, 50 mm; quantification (n = 6).
(n = 6).
ult ErgiEC-KO and Ergfl/fl mice, scale bar, 2 mm; tumor volume was quantified
the quantification of the number of endomucin-positive vessels, (n = 6), scale
igure S1.
rs
Figure 2. ERG Controls Vascular Remodeling
(A) Collagen IV (green) and isolectin B4 (IB4, red) staining of ErgiEC-KO and Ergfl/fl P6 retinal vessels. Arrows show empty collagen IV sleeves, quantification of
number of vessels, (n = 4).
(B) NG2-positive pericytes (green) associated with isolectin B4 labeled retinal vessels (red) from ErgiEC-KO and Ergfl/flmice; quantification of pixel intensity, (n = 4).
(C) Sections from B16F0 tumors grown on adult ErgiEC-KO and Ergfl/fl mice were stained for collagen IV (green) and endomucin (red); quantification of pixel
intensity, (n = 3). Arrows show empty collagen IV sleeves.
(D) Tumor sections from ErgiEC-KO and Ergfl/flmice were stained for NG2 (green) and endomucin (red); quantification of pixel intensity, (n = 3). Arrows show NG2-
negative, endomucin-positive vessels. Scale bars, 100 mm (A), scale bars, 50 mm (B–D). All graphical data are ± SEM, *p < 0.05, and ***p < 0.001. See also
Figure S2.
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Figure 3. Endothelial Canonical Wnt Signaling and b-Catenin Stability Are Regulated by ERG
(A) Staining for VE-cadherin (green), ERG (red), and isolectin B4 (IB4, blue) in ErgiEC-KO and Ergfl/fl P6 retinas. Scale bar, 50 mm; zoom, 20 mm.
(B) Relative mRNA expression of Erg and VE-cadherin in primary ErgcEC-het mouse lung EC compared to control (n = 6).
(C) b-catenin (b-cat; green) and VE-cadherin (VEC; red) staining of FITC-conjugated siCtrl and siERG (FITC; purple) treated HUVEC (n = 3). Scale bar, 20 mm.
(D and E) (D) Western blot and (E) qPCR analysis of b-catenin expression in control (siCtrl) and ERG-deficient (siERG) HUVEC (n = 4).
(F) TCF reporter activity (TOP) in control and ERG-deficient cells treated with control (Ctrl), Wnt3a, or Wnt5a conditioned medium (CM); (n = 3).
(legend continued on next page)
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(ErgcEC-het) (Figure S3A) showed an approximate 50% decrease
in VE-cadherin expression (Figure 3B), as expected.
At the junctions, VE-cadherin binds b-catenin, protecting it
from degradation; this interaction is required for the control of
junction stabilization (Dejana, 2010). b-catenin plays a pivotal
role in Wnt signaling (Goodwin and D’Amore, 2002); interest-
ingly, transcription profiling in ERG-deficient human umbilical
vein EC (HUVEC) identified several Wnt-related genes as candi-
date ERG targets (Birdsey et al., 2012) (Figure S3B). We there-
fore speculated that ERG might regulate b-catenin and Wnt
signaling in EC.
Inhibition of ERG expression in HUVEC (Figures S3C and S3D)
significantly reduced b-catenin junctional staining and protein
expression (Figures 3C and 3D). ERG regulates b-catenin protein
levels in confluent (Figure 3C) and subconfluent (Figure S3E) EC,
suggesting that this pathway functions both in quiescent and
angiogenic endothelium. However, b-catenin mRNA levels
were unaffected by ERG inhibition in HUVEC (Figures 3E and
S3F) or in primary mouse EC from ErgcEC-het mice (Figure 3H).
The decrease in b-catenin protein expression correlated with a
decrease in canonical Wnt signaling: Wnt3a stimulation of b-cat-
enin transcriptional activity was lost in ERG-deficient EC (Fig-
ure 3F). Moreover, expression levels of the Wnt target genes
Cyclin D1, Axin-2, and TCF-1 (Shtutman et al., 1999; Roose
et al., 1999; Jho et al., 2002) were decreased in ERG-deficient
HUVEC (Figure 3G) and primary mouse EC from ErgcEC-het
mice (Figure 3H). Endothelial b-catenin signaling regulates blood
brain barrier maintenance through concomitant activation of the
tight junction molecule Claudin-3 and repression of plasma-
lemma vesicle-associated protein (PLVAP) (Liebner et al.,
2008). In line with these findings, Claudin-3 expression was
significantly downregulated, while PLVAP was strongly upregu-
lated in ErgiEC-KO mouse brains (Figure 3I). Together, these re-
sults indicate that ERG regulates canonical Wnt/b-catenin
signaling in both human and mouse EC.
To confirm the relationship between ERG and b-catenin path-
ways, we used gene set enrichment analysis (GSEA) to compare
the data set from transcriptome profiling of ERG-deficient
HUVEC (Birdsey et al., 2012) with the data set from transcrip-
tome analysis of human pulmonary artery EC (HPAEC) following
b-catenin inhibition (Alastalo et al., 2011). GSEA showed a signif-
icant positive correlation between the genes regulated by ERG
and b-catenin (Figure 3J, left). Interestingly, gene ontology anal-
ysis of shared genes identified a significant number of regulators
of angiogenesis, cell adhesion, migration, and apoptosis (Fig-
ure 3J, right). These results suggest a strong relationship be-
tween these two pathways.
Since ERG inhibition decreases b-catenin protein, but not
mRNA levels, we tested whether ERG regulates b-catenin de-
gradation. b-catenin protein expression was restored in ERG-
deficient EC in the presence of the proteosomal degradation(G) qPCR of downstream b-catenin target gene expression in control and ERG-d
(H) mRNA expression of Erg, b-catenin, and its target genes Cyclin D1, Axin-2, a
(I) qPCR analysis of total brain mRNA from control and ErgiEC-KO mice for Erg, C
(J) GSEA shows enrichment and significant correlation (normalized enrichment sc
HPAEC (green curve) (Alastalo et al., 2011) and the ranked list of genes downregul
of the shared genes identified by GSEA was carried out using DAVID analysis (ri
(p < 0.01). All graphical data are ± SEM, *p < 0.05, **p < 0.01, and ***p < 0.001. S
Deveinhibitor MG132 (Figure 4A). We investigated whether ERG con-
trols b-catenin stability through VE-cadherin. In ERG-deficient
HUVEC, GFP-tagged VE-cadherin overexpression (Figure S4A)
partially restored junctional b-catenin protein levels (Figures 4B
and 4C, lane 6). However, cellular fractionation studies showed
that ERG also controls the nuclear pool of b-catenin (Figure 4C,
lane 3), which was not corrected by VE-cadherin overexpression
(Figure 4C, lane 5). This suggests that ERG controls b-catenin
also through a Wnt signaling-dependent, VE-cadherin-indepen-
dent pathway. Activation of Wnt signaling by lithium chloride
(LiCl) inhibits GSK3b, and thus degradation of cytoplasmic
b-catenin, allowing its nuclear translocation (Stambolic et al.,
1996). LiCl was able to partially normalize b-catenin nuclear
levels in ERG-deficient EC (Figure 4C, lane 7). Finally, combined
Wnt signaling activation (through LiCl) and VE-cadherin overex-
pression were able to rescue both nuclear and junctional b-cat-
enin pools in ERG-deficient EC (Figure 4C, lanes 9 and 10). These
results demonstrate that the balance between VE-cadherin-
dependent andWnt signaling-dependent pathways, whichmod-
ulates canonical Wnt/b-catenin signals in EC, is controlled by the
transcription factor ERG.
Expression of the Wnt Receptor Frizzled-4 Is Regulated
by ERG
Wnt ligands bind to receptors of the Fzd family to inhibit the
b-catenin degradation complex and activate Wnt signaling
(Goodwin and D’Amore, 2002). LiCl treatment was able to
partially stabilize b-catenin expression in ERG-deficient EC (Fig-
ure 4C, lanes 7 and 8). However, the upstream ligandWnt3a was
unable to do so (Figure S4B), suggesting a receptor-mediated
defect upstream of the degradation complex. Wnt3a interacts
with the Frizzled-4 (Fzd4) receptor (Reis and Liebner, 2013),
which is highly expressed in cultured EC (Goodwin et al.,
2006). Fzd4 was identified as a putative ERG target by transcrip-
tome analysis in HUVEC (Birdsey et al., 2012). We confirmed
that Fzd4 mRNA (Figure 4D) and protein levels (Figure 4E) were
significantly decreased in ERG-deficient HUVEC. Consistently,
Fzd4 expression was decreased in mouse EC isolated from
ErgcEC-het mice (Figure S4C).
Comparative genomic analysis of the Fzd4 promoter revealed
the presence of three highly conserved ERG DNA binding motifs
in the 800 base pair (bp) region upstream of the Fzd4 transcrip-
tion start site (Figures 4F and S4D). Analysis of the Encyclopedia
of DNA Elements (ENCODE) chromatin immunoprecipitation
sequencing (ChIP-seq) data (Birney et al., 2007) for histone
marks H3K4me1 and H3K27Ac and RNA polymerase II occu-
pancy, markers of active promoters, show that the location of
these marks correlates with the position of the ERG binding mo-
tifs (Figure 4F). ChIP-quantitative (q)PCR demonstrated that
ERG interacts directlywith the humanFzd4 promoter (Figure 4G);
specificity of the interaction was confirmed in ERG-deficient ECeficient HUVEC: Cyclin D1, Axin-2, and TCF-1 (n = 4).
nd TCF-1 in primary ErgcEC-het mouse lung EC compared to control (n = 6).
laudin-3, and PLVAP.
ore, 2.46; p < 0.001) between genes downregulated in b-catenin siRNA-treated
ated by ERG inhibition in HUVEC (Birdsey et al., 2012). Functional classification
ght). The functional categories shown displayed significant enrichment scores
ee also Figure S3.
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(Figure 4G). ERG overexpression resulted in a 6-fold transactiva-
tion of a Fzd4 promoter luciferase construct in HUVEC (Fig-
ure 4H). Finally, Fzd4 overexpression in ERG-deficient EC was
able to partially rescue Wnt3a activation of b-catenin trans-
criptional activity (Figure 4I). These data demonstrate that ERG
controls transcription of the Fzd4 receptor in EC and point to a
molecular mechanism for the VE-cadherin-independent control
of Wnt signaling by ERG.
ERG Controls Angiogenesis through Wnt Signaling
Wnt/b-catenin signaling can promote EC proliferation (Masck-
auchan et al., 2005) and induce cell cycle progression through
transcriptional activation of Cyclin D1 (Shtutman et al., 1999).
Therefore, we tested whether ERG may also control EC prolif-
eration through Wnt signaling. As shown in Figure 5A, inhibition
of ERG expression by siRNA decreased HUVEC proliferation;
LiCl, which prevents b-catenin degradation, rescued prolifera-
tion of ERG-deficient HUVEC. These results indicate that ERG
controls endothelial proliferation through the Wnt/b-catenin
pathway. We have previously shown that ERG deficiency
causes increased EC apoptosis (Birdsey et al., 2008). Combi-
nation of VE-cadherin overexpression and LiCl treatment could
completely prevent cell death in ERG-deficient cells, indicating
that ERG controls EC survival through Wnt/b-catenin signaling
(Figure S5A).
To test the functional relevance of Wnt signaling in ERG-
dependent angiogenesis, we used an in vitro sprouting assay
(Nakatsu et al., 2007). ERG-deficient HUVEC formed markedly
decreased numbers of significantly shorter sprouts (Figures
5B, panel b, 5C, and 5D). However, pretreatment of ERG-defi-
cient cells with LiCl to inhibit b-catenin degradation was able
to partially restore normal sprouting behavior of HUVEC (Fig-
ure 5B, panel d), by rescuing the number (Figure 5C) and length
(Figure 5D) of the sprouts. These results suggest that Wnt/b-cat-
enin signaling is required for ERG to control sprout formation
during angiogenesis.
To confirm that ERG controls angiogenesis and vascular
development in a Wnt/b-catenin-dependent manner in vivo, we
carried out a rescue experiment by pharmacological stabilization
of Wnt/b-catenin signaling (Griffin et al., 2011). Light microscopy
examination of the yolk sacs from NaCl (control) and LiCl treated
mice revealed a dramatic increase in perfused vessels in the yolkFigure 4. ERG Controls b-Catenin Stability through VE-Cadherin- and
(A) Western blot of b-catenin expression in control and ERG-deficient cells treate
(B) ERG (magenta), VEC (red), b-cat (green), and DAPI (blue) staining of control
VE-cadherin (VEC-GFP) adenovirus. Scale bar, 20 mm.
(C) Western blot (left) and quantification (right) of b-catenin expression in nucl
VEC-GFP adenovirus in presence or absence of LiCl. For normalization, tubulin
(D and E) (D) qPCR and (E) western blot analysis of Fzd4 expression in control a
(F) There are three putative ERG binding sites (black bars) located within the Fzd
between 100 vertebrates is shown across this region. ENCODE ChIP-seq data pr
and active transcription. Location of qPCR amplicon covering region R1 is indica
(G) ChIP-qPCR using primers to region R1 on ERG-bound chromatin from HUVEC
gene were used as a negative control. Data are shown as fold change over IgG
(H) Luciferase reporter assay, an ERG cDNA expression plasmid (pcDNA-ERG
promoter-luciferase construct (pGl4-Fzd4) in HUVEC and luciferase activity wa
activity over the empty pGL4 vector alone.
(I) TCF reporter (TOP) activity in control and ERG-deficient HUVEC treated with rW
transduced with VEC-GFP adenovirus (n = 3). All graphical data are ± SEM, *p <
Devesacs of ErgcEC-KO mutants following LiCl treatment (Figure 5E).
Endomucin staining revealed disrupted vessel morphology in
the yolk sacs from NaCl-treated ErgcEC-KO embryos, with
reduced microvasculature branching and decreased diameter
of the larger vitelline vessels (Figures 5E and 5F). LiCl treatment
of ErgcEC-KO mutants resulted in significant increase in vitelline
vessel diameter and in the remodeling of the microvascular
plexus (Figures 5E and 5F), in line with the increase in perfusion.
Wnt targets CyclinD1 and Axin2, previously shown to be
decreased in ERG-deficient endothelium (see Figures 3G and
3H), were significantly decreased in NaCl-treated ErgcEC-KO
yolk sacs compared to controls (Figure S5B). LiCl-treatment of
ErgcEC-KO yolk sacs normalized Cyclin D1 and Axin2 levels to
those observed in LiCl-treated control embryos (Figure 5G).
Interestingly, ERG targets VE-cadherin and Fzd4 were not
normalized, in line with the direct transcriptional role of ERG in
their regulation.
These results demonstrate that endothelial ERG controls em-
bryonic vascular development and angiogenesis through the
Wnt/b-catenin signaling pathway.
ERG Overexpression Stabilizes VEGF-Induced Blood
Vessels and Promotes Angiogenesis In Vivo
The data presented so far show that the transcription factor ERG
controls angiogenesis through pathwaysmediating vascular sta-
bility and growth. The importance of the coordinated regulation
of these pathways is highlighted by the variable and disap-
pointing results of clinical trials for therapeutic angiogenesis in
ischemic diseases, using the proangiogenic growth factor
VEGF. VEGF has been shown to induce the formation of unstable
and highly permeable vessels in vivo (Reginato et al., 2011), giv-
ing rise to local edema and inefficient tissue perfusion. Therefore,
we investigated the ability of ERG to stabilize new vessels
induced by VEGF in vivo. C57BL/6 mice received a subcutane-
ous injection of Matrigel supplemented with VEGF-A165 and
ERG (Ad.ERG) or Lacz (Ad.Lacz) adenovirus; basic fibroblast
growth factor (bFGF), which can induce stable new vessels in
this model (Bussolati et al., 2004), was used as control. Immuno-
fluorescence staining for the adenovirus hexon coat protein
showed localization of the adenovirus to endomucin-positive
neovessels in the Matrigel plugs (Figure S6A). In addition,
qPCR analysis confirmed significant expression of V5-taggedWnt-Dependent Mechanisms
d in presence or absence of MG132 (n = 4).
and ERG-deficient HUVEC transduced with GFP-tagged control (Ctrl-GFP) or
ear/cytoplasmic fractions of ERG-deficient HUVEC transduced with GFP or
was used as a cytoplasmic control and HDAC1 as a nuclear marker (n = 3).
nd ERG-deficient cells (n = 3).
4 locus upstream of the transcription start site (arrow); sequence conservation
ofiles for H3K4me1, H3K27Ac, and RNA polymerase II indicate open chromatin
ted.
treated with siCtrl or siERG. Primers for a downstream region within the Fzd4
(n = 3).
), or an empty expression plasmid (pcDNA) were cotransfected with a Fzd4
s measured. Values are represented as the fold change in relative luciferase
nt3a. Cells were transfected with control pCMV6 or pCMV6-Fzd4 plasmids and
0.05, **p < 0.01, and ***p < 0.001. See also Figure S4.
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ERG in Matrigel samples treated with Ad.ERG compared to
Ad.Lacz control (Figure S6B).
To evaluate the stability of the new vessels, vascular perme-
ability was measured using two different sized dextran tracers.
In the presence of bFGF (Figure 6A, top panel), the lower molec-
ular weight tetramethylrhodamine (TRITC)-dextran was fully con-
tained within the vascular structures and colocalized with the
larger molecular weight Fluorescein isothiocyanate (FITC)-
tracer, confirming that bFGF induces the formation of stable,
nonleaky vessels. Plugs containing VEGF-A165 and Ad.Lacz
revealed a less organized vascular network with the smaller mo-
lecular weight dextran dispersed both inside and outside of the
vessels (Figure 6A, middle panel, and Movie S1A). Interestingly,
overexpression of ERG in the presence of VEGF-A165 resulted in
reduced diffusion of the smaller molecular weight dextran (Fig-
ure 6A, bottom panel, and Movie S1B), indicating a more stable,
less permeable vasculature. Quantification of the net amount of
extravasated TRITC-dextran tracer shows that Ad.ERG caused
an approximate 4-fold reduction in tracer extravasation in
VEGF-A165-induced new vessels compared to Ad.Lacz control
(Figure 6B). Consistently, quantification of FITC-dextran area
showed that ERG overexpression in the presence of VEGF-
A165 resulted in an increase in perfused vessels within the Matri-
gel plug after 7 and 10 days, compared to control (Figures 6C
and S6C). ERG overexpression also resulted in a significant in-
crease in the number of new vessels within the Matrigel plug;
however this difference was observed only at the later time point
(Figure 6D), suggesting that the increase in blood vessel number
is secondary mainly to stabilization of VEGF-induced angiogen-
esis. These results confirm that ERG promotes stabilization of
VEGF-induced angiogenesis in vivo.
Pericyte recruitment is a critical step in vascular stability and
maturation, and lack of pericytes has been shown to cause
increased permeability (Hellstro¨m et al., 2001). Since pericyte
recruitment was decreased in two models of angiogenesis in
the ErgiEC-KO mice (see Figure 2), we investigated whether ERG
overexpression could increase the recruitment of vascular peri-
cytes in the in vivo Matrigel plug model. Indeed, pericyte recruit-
ment as measured by desmin staining was increased in the
Ad.ERG-treated plugs compared to controls (Figures 6E and
6F). These results suggest that ERG may promote stabilization
of angiogenesis also through control of pericyte recruitment.
DISCUSSION
Over the last decade, major progress has been made in under-
standing the molecular mechanisms that regulate angiogenesis.
However, the pathways that control vessel stability are less well
characterized. In this study, we identify a transcriptional programFigure 5. ERG Regulates Angiogenesis through Wnt/b-Catenin Signali
(A) In vitro Brdu incorporation in control and ERG-deficient HUVEC treated in pre
(B–D) (B) Representative images of EC sprouts on fibrin gel beads using siCtrl or
numbers of sprouts; and (D) tube length (n = 20).
(E) (Top) Representative whole mount images of E10.5 Ergfl/fl and ErgcEC-KO emb
(right) at E8.5 and E9.5. Scale bar, 1 mm (n = 5). (Middle and bottom panels) End
(F) Quantification of yolk sac vitelline vessel diameter.
(G) qPCR analysis of LiCl-treated Ergfl/fl and ErgcEC-KO embryo yolk sacs. Data ar
least three mice per group. All graphical data are ± SEM, *p < 0.05, **p < 0.01, a
Deveregulated by ERG that controls vascular stability and growth
through the Wnt/b-catenin pathway, in both a physiological
and pathological context.
We show that constitutive deletion of endothelial ERG in the
mouse embryo causes embryonic lethality with severe vascular
disruption. These observations are in line with a previous report
where global deletion of a subset of endothelial ERG isoforms re-
sulted in vascular defects and lethality between E10.5 and E11.5
(Vijayaraj et al., 2012). Instead of a strategy based on a posteriori
knowledge of ERG isoform expression, the Cre/LoxP system al-
lowed us to delete all endothelial isoforms of Erg, by targeting
exon 6, which encodes a region of the protein present in all iso-
forms. A previous transgenic model, where ERG’s function was
disrupted by a mutation in the DNA binding ETS domain
(ErgMld2/Mld2), caused embryonic lethality at a later stage
(E13.5) (Loughran et al., 2008) and did not appear to display early
vascular defects, suggesting that ERG’s functions in the vascu-
lature are not exclusively mediated by its DNA binding activity.
Using the inducible endothelial specific Cdh5(PAC)-iCreERT2
line, we show that ERG is required for angiogenesis in the devel-
oping retina of newborn mice and for tumor blood vessel growth
in adult mice. ERG deficiency results in vessel regression and
reduced pericyte recruitment, demonstrating that ERG controls
vascular stability. Interestingly, ERG overexpression in the in vivo
Matrigel plugmodel resulted in increased pericyte recruitment to
vessels. This suggests that ERG may promote stabilization of
angiogenesis in part through control of pericyte recruitment. A
recent paper has described a role for ETS factors (including
ERG) in arterial specification and reported increased ERG
expression in arterial-derived EC in vitro (Wythe et al., 2013).
However, in themouse retinal vasculature, ERGwas strongly ex-
pressed in all EC with no detectable difference between arteries
and veins.
The in vivo developmental vascular defects in the ErgcEC-KO
embryos are reminiscent of those associated with deletion of
endothelial b-catenin. Endothelial deletion of ERG causes em-
bryonic lethality earlier than the E12.5 reported for endothelial
deletion of b-catenin (Cattelino et al., 2003). This study proposed
that EC might not require b-catenin for early vascular develop-
ment, but rather for maintenance of vascular integrity and
vascular patterning at later stages. ERG’s regulation of other
genes involved in earlier stages of vascular development, such
as VE-cadherin, may be partly accountable for this difference
in phenotypes. Constitutive endothelial deletion of ERG also
causes diffuse hemorrhages and defects in vascular remodeling,
similar to those observed in the b-catenin deficient embryos. In
both lines, vitelline vessels of the yolk sac are significantly
smaller in diameter; however, unlike ErgcEC-KO embryos, endo-
thelial-specific loss of b-catenin does not affect vessel formationng
sence or absence of LiCl (n = 4).
siERG-treated HUVEC in the presence or absence of LiCl; (C) quantification of
ryo yolk sacs from pregnant female mice treated with either NaCl (left) or LiCl
omucin staining of yolk sac vasculature; scale bar, 100 mm.
e expressed as fold change versus NaCl-treated Ergfl/fl and are ± SEM from at
nd ***p < 0.001. See also Figure S5.
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Figure 6. ERG Stabilizes Angiogenesis In Vivo
Matrigel containing bFGF or VEGF with adenovirus expressing either Lacz (Ad.Lacz) or ERG (Ad.ERG) was injected into C57BL6 mice. There were two labeled
dextran molecules of different molecular weights, 23106MW (FITC, green) and 4.43104 MW (TRITC, red), that were injected intravenously 15 min prior to
harvesting plugs.
(legend continued on next page)
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in the head, but causes hyperbranching of intersomitic vessels
(Corada et al., 2010). Thus, embryonic mouse phenotypes of
ERG versus b-catenin endothelial deletion show similarities,
but not complete overlap, as expected, given the complex role
of ERG as a transcriptional regulator of multiple vascular path-
ways. Crucially, the yolk sac vascular defects in the ErgcEC-KO
and expression of Wnt targets were rescued by in vivo treatment
with LiCl. Althoughwe cannot completely rule out non-EC effects
of LiCl, these experiments clearly demonstrate that ERG controls
vascular development through Wnt signaling.
Interestingly, similar angiogenic defects are observed in the
retinas from ErgiEC-KO and from the reported endothelial-specific
b-catenin and Fzd4 knockout mice (Xu et al., 2004; Ye et al.,
2009; Phng et al., 2009; Corada et al., 2010). Whether ERG is
implicated in human ocular diseases, including Norrie disease
and familial exudative vitreoretinopathy, which are associated
with Fzd4 and its ligand Norrin (Xu et al., 2004), remains to be es-
tablished. In line with our data, a link between Fzd4 and ERG has
been previously observed in prostate cancer (Gupta et al., 2010).
Interestingly, our results show that ERG deficiency results in
about 50% reduction in Fzd4 protein, but completely abrogates
Wnt luciferase reporter activity in response to Wnt3a. This sug-
gests that ERG’s control of other nodes in this pathway,
including repression of the Wnt inhibitor DACT1 (Zhang et al.,
2006) and activation of the transcription factor TCF4 (Wang
et al., 2002), may be important.
Canonical Wnt signaling promotes EC survival, junction stabi-
lization, proliferation, and pericyte recruitment and is essential
for vessel stability (Cattelino et al., 2003; Phng et al., 2009;
reviewed in Franco et al., 2009; Dejana, 2010). In this study,
we establish ERG as a regulator of canonical Wnt/b-catenin
signaling, and therefore identify a connection between two key
transcriptional regulators essential for EC function. We show
that ERG controls cell survival, proliferation, angiogenesis, and
vessel stability through b-catenin. Whether ERG controls peri-
cyte recruitment via Wnt signaling remains to be elucidated; pre-
liminary evidence suggests that ERG regulates expression of the
junction molecule and b-catenin transcriptional target N-cad-
herin (data not shown), which plays a crucial role in pericyte
attachment during vessel formation (Giampietro et al., 2012;
Gerhardt et al., 2000). Our data show that ERG controls Wnt/
b-catenin levels and signaling through VE-cadherin-dependent
and -independent pathways both in confluent, quiescent mono-
layers and in subconfluent, proliferating cells. The balance be-
tween VE-cadherin and Wnt-dependent signals controls b-cate-
nin cellular localization and activity. It has been suggested that
b-catenin could function to increase cell plasticity and sensitivity
to extracellular signals (Franco et al., 2009). Transcriptional ac-
tivity of ERG itself has been shown to be modulated by extracel-
lular signals (Wythe et al., 2013). Thus, we propose that in EC,
ERG is required to maintain homeostatic levels of b-catenin pro-(A) 3D rendering of confocal microscopy images of whole-mount Matrigel plugs
shows localization of the tracers.
(B) Vessel permeability was quantified by measuring the amount of dextran-TRIT
(C) Perfused vessels were quantified by measuring the area of dextran-FITC with
(D) Vessel density was quantified by measuring the area of isolectin B4 within th
(E) Endomucin (red), desmin-positive pericytes (green), and Draq5 (blue) staining
(F) Quantification of pericyte coverage, pixel intensity (n = 8). All graphical data a
Devetein, the output of which can be modulated according to the
growth and survival signals it encounters, providing the balance
between proliferation and stability required in a nascent blood
vessel.
Dysregulation of the Wnt/b-catenin signaling pathway is
frequently observed in many types of cancer. Constitutive Wnt
signaling activation caused by mutations in b-catenin or genes
that control b-catenin stability has been associated with aberrant
cell proliferation and subsequent cancer progression (reviewed
in Giles et al., 2003). Wnt signaling has been shown to be a crit-
ical mediator of ERG-induced oncogenesis in several types
of cancer, where aberrant ERG overexpression is a marker of
aggressive malignancy and associated with increased prolifera-
tion (Gupta et al., 2010; Wu et al., 2013; Li et al., 2011; Moch-
mann et al., 2011). This is in contrast with its role in healthy endo-
thelium, where ERG promotes homeostasis and stability. The
reasons for this discrepancy are unknown and may be linked
to the lack of balance between growth and survival signals,
due to disrupted cell-cell signaling inmalignant cells, thus driving
the cells to a proliferative fate. Thus, strategies to control ERG’s
activity in malignant cells through cell-cell adhesion signals
might be worthy of investigation.
Finally, in this study, we explore the potential for ERG in pro-
moting vascular stability during VEGF-induced angiogenesis.
Numerous studies have shown that the new vasculature induced
by VEGF in vivo, to promote revascularization in ischemic dis-
eases (Zachary and Morgan, 2011), can be dysfunctional due
to vascular instability and increased permeability (Reginato
et al., 2011). Here, we show that overexpression of ERG can
reduce permeability and promote VEGF-induced angiogenesis
in vivo. Combined with the homeostatic and anti-inflammatory
role of ERG (Sperone et al., 2011; Yuan et al., 2009), these results
establish the ERG pathway as a potential target to promote
vascular quiescence and stability.EXPERIMENTAL PROCEDURES
Detailed methods are available in the Supplemental Experimental Procedures.Mice and Breeding
Generation of Erg floxed mice was carried out by genOway. LoxP sequences
were inserted around exon 6. Deletion of this exon leads to a frameshift
mutation resulting in a premature stop codon in exon 7. Ergfl/fl mice were
crossed with the following Cre transgenic deleter lines: Cdh5(PAC)-CreERT2
(Wang et al., 2010) and Tie2-Cre (Kisanuki et al., 2001). All experiments were
conducted in accordance with the Animals (Scientific Procedures) Act of
1986.
Postnatal Retinal Angiogenesis
Mice were administered Tamoxifen (50 mg per mouse; Sigma) by intraperito-
neal injection (IP) at postnatal (P) day 1, P2 and P3. Retinas were collected
at P6 and processed as described (Pitulescu et al., 2010).perfused with the dextran tracers. Cross sectioning through neovessels (right)
C present outside of the dextran-FITC positive vessels, arbitrary units (n = 3).
in the Matrigel plug after 3, 7, and 10 days (n = 4).
e Matrigel plug after 3, 7, and 10 days (n = 4).
of cryosections from Matrigel plugs implanted for 7 days; scale bar, 20 mm.
re ± SEM, *p < 0.05, and **p < 0.01. See also Figure S6.
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Syngeneic Tumor Experiments
Mouse melanoma B16F0 tumors were grown in tamoxifen-treated adult Ergfl/fl
and ErgiEC-KO mice as described (Reynolds et al., 2002).
In Vivo LiCl Treatment
LiCl or NaCl (400 mg/kg, dissolved in water) was injected IP into pregnant
female mice at E8.5 and E9.5. Embryos were harvested at E10.5 and yolk
sac vasculature was analyzed by light microscopy and immunostaining.
In Vivo Matrigel Angiogenesis Assay
C57BL/6mice received a subcutaneous injection ofMatrigel (BDBiosciences),
as described (Birdsey et al., 2008). Matrigel was supplemented with 80 nano-
gram (ng)/ml bFGF (R&D Systems), or with 100 ng/ml murine VEGF-A165 (Pe-
protech) containing 109 plaque-forming unit adenovirus expressing either Lacz
or ERG. After 3, 7, or 10 days, 100 ml of a 1:1 mixture of 10 mg/ml Dextran:FITC
(23106 MW) and Dextran:TRITC (4.43104 MW) was injected intravenously
15 min prior to harvesting plugs. Plugs were imaged whole-mount using
confocal microscopy. Volocity software (Perkin Elmer) was used to reconstruct
3D images of the vessels from serial Z-sections. The extent of TRITC-dextran
tracer extravasation was quantified by subtracting the signal corresponding to
the FITC-dextran tracer (intravascular) from the signal corresponding to the
TRITC-dextran tracer (intravascular + extravascular).
Isolation of Mouse Lung Endothelial Cells
Primary mouse lung EC were isolated from control Ergfl/fl and ErgcEC-het mice
as described (Reynolds et al., 2002). Rat APC-CD31, anti-ICAM-2, and anti-rat
PE antibodies (all BD Biosciences) were used to assess the EC purity by flow
cytometric analysis using a Cyan flow cytometer (Beckman Coulter).
Cell Culture
Primary HUVEC were harvested from umbilical cords (Birdsey et al., 2008).
Human ERG expression was inhibited using either GeneBloc antisense ol-
igonucleotides (Silence Therapeutics) (McLaughlin et al., 2001) or siRNA
against ERG (Hs_ERG_7); both denoted as siERG in the text. Control Gen-
eBloc antisense or AllStars Negative Control siRNA (QIAGEN) are denoted
as siCtrl.
ChIP-qPCR
ChIP was performed using ChIP-IT express (Active Motif) as previously
described (Birdsey et al., 2012).
Plasmid Transfections and Reporter Assays
For Fzd4 transactivation assays, a 1,010-bp region of the Fzd4 promoter
(SwitchGear, Active Motif) was cloned into the pGL4 Luciferase Reporter Vec-
tor (Promega). TCF reporter constructs TOPFLASH and FOPFLASHwere used
to measure the transcriptional activity of b-catenin/TCF (Korinek et al., 1997).
In some experiments, cells were cotransfected with a pCMV6-Fzd4 expres-
sion construct (Origene). Reporter assays were performed using the Dual-
Luciferase Reporter Assay System (Promega).
BrdU In Vitro Proliferation Assay
Cell proliferation was determined in vitro using a BrdU proliferation ELISA kit
(Roche) according to the manufacturer’s instructions.
Fibrin Gel Bead Assay
The 3D in vitro model of angiogenesis was performed as described previously
(Nakatsu et al., 2007).
Statistical Analysis
Values are presented as means ± SEM. Statistical significance was deter-
mined by using unpaired two-tailed Student’s t test. Differences were consid-
ered significant with a p value < 0.05.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and two movies and can be found with this article online at
http://dx.doi.org/10.1016/j.devcel.2014.11.016.94 Developmental Cell 32, 82–96, January 12, 2015 ª2015 The AuthoAUTHOR CONTRIBUTIONS
G.M.B. designed, carried out, and supervised in vivo and in vitro experiments,
analyzed and interpreted results, and wrote the manuscript. A.V.S. designed
and carried out in vitro experiments, analyzed, interpreted, and conceptual-
ized results, and wrote the manuscript. N.D. designed and performed in vivo
experiments, analyzed, and interpreted results. B.G. provided advice on bio-
informatic analysis and interpretation and contributed to scientific discussion;
Y.Y. performed bioinformatic analysis and interpretation; and L.R. and K.H.D.
performed and supervised the tumor angiogenesis experiments, analyzed re-
sults, and contributed to scientific discussion. L.O.A. and S.T.K. performed ex-
periments and analyzed results. I.M.A. provided advice on retina isolation and
optimized ERG retinal staining; E.D. provided reagents and contributed to sci-
entific discussion; J.C.M. contributed to scientific discussion; H.G. provided
advice and contributed to scientific discussion; R.H.A. assisted in the design
of the transgenic mice, provided reagents, advice, and contributed to scientific
discussion; and A.M.R. provided funding, conceived, designed, and super-
vised the study, interpreted results, and wrote the manuscript.ACKNOWLEDGMENTS
We thank M. Pitulescu (Max Planck Institute for Molecular Biomedicine,
Mu¨nster, Germany) for advice; H. Clevers (Hubrecht Institute for Develop-
mental Biology and Stem Cell Research, Utrecht, Netherlands) for providing
the TOPFLASH TCF reporter and control FOPFLASH plasmids; F.W. Luscin-
skas (Harvard Medical School, Boston, MA) for providing the VE-cadherin
GFP adenovirus; L. Lawrence (Imperial College London, UK) for technical
assistance; G. Cossu (University of Manchester, UK) for critical reading of
the manuscript; and A. Taddei (Cancer Research UK, London, UK), M. Johns
(Imperial College London, UK), and D. Haskard (Imperial College London, UK)
for helpful discussions. This work was funded by grants from the British Heart
Foundation (PG/09/096 and RG/11/17/29256). A.V.S. is a recipient of a Na-
tional Lung and Heart Institute Foundation Studentship. I.M.A. is a recipient
of a DOC-fFORTE fellowship of the Austrian Academy of Sciences at the Lon-
don Research Institute.
Received: June 13, 2014
Revised: September 24, 2014
Accepted: November 10, 2014
Published: January 12, 2015
REFERENCES
Alastalo, T.P., Li, M., Perez, Vde.J., Pham, D., Sawada, H., Wang, J.K.,
Koskenvuo, M., Wang, L., Freeman, B.A., Chang, H.Y., and Rabinovitch, M.
(2011). Disruption of PPARg/b-catenin-mediated regulation of apelin impairs
BMP-induced mouse and human pulmonary arterial EC survival. J. Clin.
Invest. 121, 3735–3746.
Baltzinger, M., Mager-Heckel, A.M., and Remy, P. (1999). Xl erg: expression
pattern and overexpression during development plead for a role in endothelial
cell differentiation. Dev. Dyn. 216, 420–433.
Birdsey, G.M., Dryden, N.H., Amsellem, V., Gebhardt, F., Sahnan, K., Haskard,
D.O., Dejana, E., Mason, J.C., and Randi, A.M. (2008). Transcription factor Erg
regulates angiogenesis and endothelial apoptosis through VE-cadherin. Blood
111, 3498–3506.
Birdsey, G.M., Dryden, N.H., Shah, A.V., Hannah, R., Hall, M.D., Haskard,
D.O., Parsons, M., Mason, J.C., Zvelebil, M., Gottgens, B., et al. (2012). The
transcription factor Erg regulates expression of histone deacetylase 6 andmul-
tiple pathways involved in endothelial cell migration and angiogenesis. Blood
119, 894–903.
Birney, E., Stamatoyannopoulos, J.A., Dutta, A., Guigo´, R., Gingeras, T.R.,
Margulies, E.H., Weng, Z., Snyder, M., Dermitzakis, E.T., Thurman, R.E.,
et al.; ENCODE Project Consortium; NISC Comparative Sequencing
Program; Baylor College of Medicine Human Genome Sequencing Center;
Washington University Genome Sequencing Center; Broad Institute;
Children’s Hospital Oakland Research Institute (2007). Identification andrs
analysis of functional elements in 1% of the human genome by the ENCODE
pilot project. Nature 447, 799–816.
Bussolati, B., Ahmed, A., Pemberton, H., Landis, R.C., Di Carlo, F., Haskard,
D.O., and Mason, J.C. (2004). Bifunctional role for VEGF-induced heme oxy-
genase-1 in vivo: induction of angiogenesis and inhibition of leukocytic infiltra-
tion. Blood 103, 761–766.
Cattelino, A., Liebner, S., Gallini, R., Zanetti, A., Balconi, G., Corsi, A., Bianco,
P., Wolburg, H., Moore, R., Oreda, B., et al. (2003). The conditional inactivation
of the beta-catenin gene in endothelial cells causes a defective vascular
pattern and increased vascular fragility. J. Cell Biol. 162, 1111–1122.
Corada, M., Nyqvist, D., Orsenigo, F., Caprini, A., Giampietro, C., Taketo,
M.M., Iruela-Arispe, M.L., Adams, R.H., and Dejana, E. (2010). The Wnt/
beta-catenin pathway modulates vascular remodeling and specification by
upregulating Dll4/Notch signaling. Dev. Cell 18, 938–949.
Dejana, E. (2010). The role of wnt signaling in physiological and pathological
angiogenesis. Circ. Res. 107, 943–952.
Franco, C.A., Liebner, S., and Gerhardt, H. (2009). Vascular morphogenesis: a
Wnt for every vessel? Curr. Opin. Genet. Dev. 19, 476–483.
Gerhardt, H., Wolburg, H., and Redies, C. (2000). N-cadherin mediates peri-
cytic-endothelial interaction during brain angiogenesis in the chicken. Dev.
Dyn. 218, 472–479.
Giampietro, C., Taddei, A., Corada, M., Sarra-Ferraris, G.M., Alcalay, M.,
Cavallaro, U., Orsenigo, F., Lampugnani, M.G., and Dejana, E. (2012).
Overlapping and divergent signaling pathways of N-cadherin and VE-cadherin
in endothelial cells. Blood 119, 2159–2170.
Giles, R.H., van Es, J.H., and Clevers, H. (2003). Caught up in aWnt storm:Wnt
signaling in cancer. Biochim. Biophys. Acta 1653, 1–24.
Goodwin, A.M., and D’Amore, P.A. (2002). Wnt signaling in the vasculature.
Angiogenesis 5, 1–9.
Goodwin, A.M., Sullivan, K.M., and D’Amore, P.A. (2006). Cultured endothelial
cells display endogenous activation of the canonical Wnt signaling pathway
and express multiple ligands, receptors, and secreted modulators of Wnt
signaling. Dev. Dyn. 235, 3110–3120.
Gory, S., Dalmon, J., Prandini, M.H., Kortulewski, T., de Launoit, Y., and
Huber, P. (1998). Requirement of a GT box (Sp1 site) and two Ets binding sites
for vascular endothelial cadherin gene transcription. J. Biol. Chem. 273, 6750–
6755.
Griffin, C.T., Curtis, C.D., Davis, R.B., Muthukumar, V., and Magnuson, T.
(2011). The chromatin-remodeling enzyme BRG1 modulates vascular Wnt
signaling at two levels. Proc. Natl. Acad. Sci. USA 108, 2282–2287.
Gupta, S., Iljin, K., Sara, H., Mpindi, J.P., Mirtti, T., Vainio, P., Rantala, J.,
Alanen, K., Nees, M., and Kallioniemi, O. (2010). FZD4 as a mediator of ERG
oncogene-induced WNT signaling and epithelial-to-mesenchymal transition
in human prostate cancer cells. Cancer Res. 70, 6735–6745.
Hellstro¨m, M., Gerhardt, H., Kale´n, M., Li, X., Eriksson, U., Wolburg, H., and
Betsholtz, C. (2001). Lack of pericytes leads to endothelial hyperplasia and
abnormal vascular morphogenesis. J. Cell Biol. 153, 543–553.
Jain, R.K. (2003). Molecular regulation of vessel maturation. Nat. Med. 9,
685–693.
Jho, E.H., Zhang, T., Domon, C., Joo, C.K., Freund, J.N., and Costantini, F.
(2002). Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a
negative regulator of the signaling pathway. Mol. Cell. Biol. 22, 1172–1183.
Kisanuki, Y.Y., Hammer, R.E., Miyazaki, J., Williams, S.C., Richardson, J.A.,
and Yanagisawa, M. (2001). Tie2-Cre transgenic mice: a new model for endo-
thelial cell-lineage analysis in vivo. Dev. Biol. 230, 230–242.
Korinek, V., Barker, N., Morin, P.J., van Wichen, D., de Weger, R., Kinzler,
K.W., Vogelstein, B., and Clevers, H. (1997). Constitutive transcriptional acti-
vation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science
275, 1784–1787.
Korn, C., Scholz, B., Hu, J., Srivastava, K., Wojtarowicz, J., Arnsperger, T.,
Adams, R.H., Boutros, M., Augustin, H.G., and Augustin, I. (2014).
Endothelial cell-derived non-canonical Wnt ligands control vascular pruning
in angiogenesis. Development 141, 1757–1766.DeveLi, Y., Kong, D., Wang, Z., Ahmad, A., Bao, B., Padhye, S., and Sarkar, F.H.
(2011). Inactivation of AR/TMPRSS2-ERG/Wnt signaling networks attenuates
the aggressive behavior of prostate cancer cells. Cancer Prev. Res. (Phila.) 4,
1495–1506.
Liebner, S., Corada, M., Bangsow, T., Babbage, J., Taddei, A., Czupalla, C.J.,
Reis, M., Felici, A., Wolburg, H., Fruttiger, M., et al. (2008). Wnt/beta-catenin
signaling controls development of the blood-brain barrier. J. Cell Biol. 183,
409–417.
Liu, F., and Patient, R. (2008). Genome-wide analysis of the zebrafish ETS fam-
ily identifies three genes required for hemangioblast differentiation or angio-
genesis. Circ. Res. 103, 1147–1154.
Loughran, S.J., Kruse, E.A., Hacking, D.F., de Graaf, C.A., Hyland, C.D.,
Willson, T.A., Henley, K.J., Ellis, S., Voss, A.K., Metcalf, D., et al. (2008). The
transcription factor Erg is essential for definitive hematopoiesis and the func-
tion of adult hematopoietic stem cells. Nat. Immunol. 9, 810–819.
Masckauchan, T.N., Shawber, C.J., Funahashi, Y., Li, C.M., and Kitajewski, J.
(2005). Wnt/beta-catenin signaling induces proliferation, survival and inter-
leukin-8 in human endothelial cells. Angiogenesis 8, 43–51.
McLaughlin, F., Ludbrook, V.J., Cox, J., von Carlowitz, I., Brown, S., and
Randi, A.M. (2001). Combined genomic and antisense analysis reveals that
the transcription factor Erg is implicated in endothelial cell differentiation.
Blood 98, 3332–3339.
Mochmann, L.H., Bock, J., Ortiz-Ta´nchez, J., Schlee, C., Bohne, A., Neumann,
K., Hofmann,W.K., Thiel, E., and Baldus, C.D. (2011). Genome-wide screen re-
veals WNT11, a non-canonical WNT gene, as a direct target of ETS transcrip-
tion factor ERG. Oncogene 30, 2044–2056.
Nakatsu, M.N., Davis, J., and Hughes, C.C. (2007). Optimized fibrin gel bead
assay for the study of angiogenesis. J. Vis. Exp. 186.
Phng, L.K., Potente, M., Leslie, J.D., Babbage, J., Nyqvist, D., Lobov, I., Ondr,
J.K., Rao, S., Lang, R.A., Thurston, G., and Gerhardt, H. (2009). Nrarp coordi-
nates endothelial Notch and Wnt signaling to control vessel density in angio-
genesis. Dev. Cell 16, 70–82.
Pitulescu, M.E., Schmidt, I., Benedito, R., and Adams, R.H. (2010). Inducible
gene targeting in the neonatal vasculature and analysis of retinal angiogenesis
in mice. Nat. Protoc. 5, 1518–1534.
Randi, A.M., Sperone, A., Dryden, N.H., and Birdsey, G.M. (2009). Regulation
of angiogenesis by ETS transcription factors. Biochem. Soc. Trans. 37, 1248–
1253.
Reginato, S., Gianni-Barrera, R., and Banfi, A. (2011). Taming of the wild
vessel: promoting vessel stabilization for safe therapeutic angiogenesis.
Biochem. Soc. Trans. 39, 1654–1658.
Reis, M., and Liebner, S. (2013). Wnt signaling in the vasculature. Exp. Cell
Res. 319, 1317–1323.
Reynolds, L.E., Wyder, L., Lively, J.C., Taverna, D., Robinson, S.D., Huang, X.,
Sheppard, D., Hynes, R.O., and Hodivala-Dilke, K.M. (2002). Enhanced path-
ological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integ-
rins. Nat. Med. 8, 27–34.
Roose, J., Huls, G., van, B.M., Moerer, P., van der Horn, K., Goldschmeding,
R., Logtenberg, T., and Clevers, H. (1999). Synergy between tumor suppressor
APC and the beta-catenin-Tcf4 target Tcf1. Science 285, 1923–1926.
Shtutman, M., Zhurinsky, J., Simcha, I., Albanese, C., D’Amico, M., Pestell, R.,
and Ben-Ze’ev, A. (1999). The cyclin D1 gene is a target of the beta-catenin/
LEF-1 pathway. Proc. Natl. Acad. Sci. USA 96, 5522–5527.
Sperone, A., Dryden, N.H., Birdsey, G.M., Madden, L., Johns, M., Evans, P.C.,
Mason, J.C., Haskard, D.O., Boyle, J.J., Paleolog, E.M., and Randi, A.M.
(2011). The transcription factor Erg inhibits vascular inflammation by repres-
sing NF-kappaB activation and proinflammatory gene expression in endothe-
lial cells. Arterioscler. Thromb. Vasc. Biol. 31, 142–150.
Stambolic, V., Ruel, L., and Woodgett, J.R. (1996). Lithium inhibits glycogen
synthase kinase-3 activity and mimics wingless signalling in intact cells.
Curr. Biol. 6, 1664–1668.
Vijayaraj, P., Le Bras, A., Mitchell, N., Kondo, M., Juliao, S., Wasserman, M.,
Beeler, D., Spokes, K., Aird, W.C., Baldwin, H.S., and Oettgen, P. (2012).lopmental Cell 32, 82–96, January 12, 2015 ª2015 The Authors 95
Erg is a crucial regulator of endocardial-mesenchymal transformation during
cardiac valve morphogenesis. Development 139, 3973–3985.
Wang, X., Xiao, Y., Mou, Y., Zhao, Y., Blankesteijn, W.M., and Hall, J.L. (2002).
A role for the beta-catenin/T-cell factor signaling cascade in vascular remod-
eling. Circ. Res. 90, 340–347.
Wang, Y., Nakayama, M., Pitulescu, M.E., Schmidt, T.S., Bochenek, M.L.,
Sakakibara, A., Adams, S., Davy, A., Deutsch, U., Lu¨thi, U., et al. (2010).
Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis.
Nature 465, 483–486.
Wu, L., Zhao, J.C., Kim, J., Jin, H.J., Wang, C.Y., and Yu, J. (2013). ERG is a
critical regulator of Wnt/LEF1 signaling in prostate cancer. Cancer Res. 73,
6068–6079.
Wythe, J.D., Dang, L.T., Devine, W.P., Boudreau, E., Artap, S.T., He, D.,
Schachterle, W., Stainier, D.Y., Oettgen, P., Black, B.L., et al. (2013). ETS fac-
tors regulate Vegf-dependent arterial specification. Dev. Cell 26, 45–58.
Xu, Q., Wang, Y., Dabdoub, A., Smallwood, P.M., Williams, J., Woods, C.,
Kelley, M.W., Jiang, L., Tasman, W., Zhang, K., and Nathans, J. (2004).
Vascular development in the retina and inner ear: control by Norrin and
Frizzled-4, a high-affinity ligand-receptor pair. Cell 116, 883–895.96 Developmental Cell 32, 82–96, January 12, 2015 ª2015 The AuthoYe, X., Wang, Y., Cahill, H., Yu, M., Badea, T.C., Smallwood, P.M., Peachey,
N.S., and Nathans, J. (2009). Norrin, frizzled-4, and Lrp5 signaling in endothe-
lial cells controls a genetic program for retinal vascularization. Cell 139,
285–298.
Yuan, L., Nikolova-Krstevski, V., Zhan, Y., Kondo, M., Bhasin, M., Varghese,
L., Yano, K., Carman, C.V., Aird, W.C., and Oettgen, P. (2009).
Antiinflammatory effects of the ETS factor ERG in endothelial cells are medi-
ated through transcriptional repression of the interleukin-8 gene. Circ. Res.
104, 1049–1057.
Yuan, L., Le Bras, A., Sacharidou, A., Itagaki, K., Zhan, Y., Kondo, M., Carman,
C.V., Davis, G.E., Aird, W.C., and Oettgen, P. (2012). ETS-related gene (ERG)
controls endothelial cell permeability via transcriptional regulation of the clau-
din 5 (CLDN5) gene. J. Biol. Chem. 287, 6582–6591.
Zachary, I., and Morgan, R.D. (2011). Therapeutic angiogenesis for cardiovas-
cular disease: biological context, challenges, prospects. Heart 97, 181–189.
Zhang, L., Gao, X., Wen, J., Ning, Y., and Chen, Y.G. (2006). Dapper 1 antag-
onizes Wnt signaling by promoting dishevelled degradation. J. Biol. Chem.
281, 8607–8612.rs
